FEM1B

Across TCGA pan-cancer cohorts, FEM1B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FEM1B data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FEM1B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FEM1B expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where FEM1B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	0.314	1.000	.008	33	view →
PDAC	OS	Tertile	All	0.694	0.249	.002	27	view →
HNSC	DFS	Quartile	All	0.406	0.966	.026	4	view →
UCEC	DFS	Quartile	All	0.966	0.838	.047	2	view →
LUAD	OS	Median	All	0.780	0.890	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FEM1B–CCRCC (OS)

Open the CCRCC breakdown →